Research Protocol - Post-kala-azar Dermal Leishmaniasis (PKDL): a prospective observational study of the effectiveness and safety of an ambulatory short course treatment with AmBisome* 15 mg/kg total dose

Hdl Handle:
http://hdl.handle.net/10144/322173
Title:
Research Protocol - Post-kala-azar Dermal Leishmaniasis (PKDL): a prospective observational study of the effectiveness and safety of an ambulatory short course treatment with AmBisome* 15 mg/kg total dose
Authors:
Ritmeijer, Koert; Kumar Das, Asish; Ahmed, Be-Nazir; den Boer, Margriet; Almeida, Patrick; Verputten, Meggy
Abstract:
General objective To evaluate the effectiveness and safety of PKDL treatment with AmBisome 15 mg/kg total dose, given over 15 days in 5 infusions (twice weekly) of 3mg/kg on an ambulatory basis in a primary health care setting. Primary objective: to evaluate the effectiveness of AmBisome 15 mg/kg total dose at 12 M Secondary objective: • Evaluate the safety of AmBisome 3mg/kg x 5 infusions (twice weekly) (15 mg/kg total dose) • Evaluate the occurrence of hypokalaemia • Evaluate at which point in time lesions start to respond to treatment.
Affiliation:
MSF-Holland, Amsterdam, The Netherlands; MSF-Holland, Fulbaria, Bangladesh; CDC, (DGHS); MSF-Holland, Amsterdam, The Netherlands; MSF-Holland, Dhaka, Bangladesh; MSF-Holland, Amsterdam, The Netherlands
Issue Date:
Jun-2014
URI:
http://hdl.handle.net/10144/322173
Type:
Other
Language:
en
Description:
Research protocol. These materials can be used, adapted and copied as long as citation of the source is given including the direct URL to the material. This work is licensed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0/ https://i.creativecommons.org/l/by/4.0/88x31.png
Appears in Collections:
MSF Research Protocols

Full metadata record

DC FieldValue Language
dc.contributor.authorRitmeijer, Koert; Kumar Das, Asish; Ahmed, Be-Nazir; den Boer, Margriet; Almeida, Patrick; Verputten, Meggyen_GB
dc.date.accessioned2014-06-23T15:06:32Z-
dc.date.available2014-06-23T15:06:32Z-
dc.date.issued2014-06-
dc.identifier.urihttp://hdl.handle.net/10144/322173-
dc.descriptionResearch protocol. These materials can be used, adapted and copied as long as citation of the source is given including the direct URL to the material. This work is licensed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0/ https://i.creativecommons.org/l/by/4.0/88x31.pngen_GB
dc.description.abstractGeneral objective To evaluate the effectiveness and safety of PKDL treatment with AmBisome 15 mg/kg total dose, given over 15 days in 5 infusions (twice weekly) of 3mg/kg on an ambulatory basis in a primary health care setting. Primary objective: to evaluate the effectiveness of AmBisome 15 mg/kg total dose at 12 M Secondary objective: • Evaluate the safety of AmBisome 3mg/kg x 5 infusions (twice weekly) (15 mg/kg total dose) • Evaluate the occurrence of hypokalaemia • Evaluate at which point in time lesions start to respond to treatment.en_GB
dc.language.isoenen
dc.subjectPKDLen_GB
dc.subjectAmbisomeen_GB
dc.subjectvisceral leishmaniasisen_GB
dc.titleResearch Protocol - Post-kala-azar Dermal Leishmaniasis (PKDL): a prospective observational study of the effectiveness and safety of an ambulatory short course treatment with AmBisome* 15 mg/kg total doseen
dc.typeOtheren
dc.contributor.departmentMSF-Holland, Amsterdam, The Netherlands; MSF-Holland, Fulbaria, Bangladesh; CDC, (DGHS); MSF-Holland, Amsterdam, The Netherlands; MSF-Holland, Dhaka, Bangladesh; MSF-Holland, Amsterdam, The Netherlandsen_GB
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.